

Registered number  
11030393

PHARMAVACCS LTD

Filleted Accounts

31 October 2023

**PHARMAVACCS LTD****Registered number:** 11030393**Balance Sheet****as at 31 October 2023**

	Notes	2023 £	2022 £
<b>Fixed assets</b>			
Intangible assets	3	49,400	60,054
<b>Current assets</b>			
Debtors	4	7,200	-
Cash at bank and in hand		17,758	17,747
		<u>24,958</u>	<u>17,747</u>
<b>Creditors: amounts falling due within one year</b>	5	(39,830)	(55,158)
<b>Net current liabilities</b>		<u>(14,872)</u>	<u>(37,411)</u>
<b>Total assets less current liabilities</b>		<u>34,528</u>	<u>22,643</u>
<b>Creditors: amounts falling due after more than one year</b>	6	(290,000)	(270,000)
<b>Net liabilities</b>		<u>(255,472)</u>	<u>(247,357)</u>
<b>Capital and reserves</b>			
Called up share capital		1,500	1,500
Profit and loss account		(256,972)	(248,857)
<b>Shareholders' funds</b>		<u>(255,472)</u>	<u>(247,357)</u>

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.

AISHA SULEMAN

Director

Approved by the board on 23 November 2023

# PHARMAVACCS LTD

## Notes to the Accounts

for the year ended 31 October 2023

### 1 Accounting policies

#### ***Basis of preparation***

The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

#### ***Turnover***

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

#### ***Intangible fixed assets***

Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses.

#### ***Tangible fixed assets***

Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:

Plant and machinery	over 10 years
---------------------	---------------

#### ***Creditors***

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

### 2 Employees

	2023	2022
	Number	Number
Average number of persons employed by the company	2	2

### 3 Intangible fixed assets

	£
Research & Development:	

#### **Cost**

At 1 November 2022	106,536
At 31 October 2023	106,536

#### **Amortisation**

At 1 November 2022	46,482
Provided during the year	10,654
At 31 October 2023	57,136

#### **Net book value**

At 31 October 2023	49,400
--------------------	--------

At 31 October 2022

60,054

Research & Development is being written off in equal annual instalments over its estimated economic life of 10 years.

4 Debtors	2023	2022
	£	£
Trade debtors	7,200	-

5 Creditors: amounts falling due within one year	2023	2022
	£	£
Other creditors	39,830	55,158

6 Creditors: amounts falling due after one year	2023	2022
	£	£
Other Loans - Prestford Ltd	60,000	60,000
Directors Loans	230,000	210,000
	290,000	270,000

7 Loans from directors				
Description and conditions	B/fwd	Paid	Repaid	C/fwd
	£	£	£	£
WAQQASS SHEIKH	16,800		(16,800)	-
AISHA SULEMAN	10,000		-	10,000
SHATA ISMAIEL SALMAN AL JUBOORI	200,000		-	200,000
	226,800	-	(16,800)	210,000

#### 8 Controlling party

The company is under the ultimate control of Mr Waqqass Sheikh by virtue of him and his wife owning more than 50% of the issued share capital.

Share capital	Nominal value	2023 Number	2023 £	2022 £
Allotted, called up and fully paid:				
Ordinary shares	£1 each		1,500	1,000
	Nominal value	Number	Amount £	
Shares issued during the period:				
Ordinary shares	£1 each	-	-	-

<b><u>Shareholders Details</u></b>	<b><u>Nominal Value</u></b>	<b><u>Number</u></b>	<b><u>Amount</u></b>
Waqqass Sheikh	£1.00	450	£450.00
Rizwana Sheikh	£1.00	450	£450.00
Aisha Suleman	£1.00	100	£100.00
Shatha Ismaiel Salman al Juboori	£1.00	250	£250.00
Zabir Hakim	£1.00	250	£250.00

## **9 Other information**

PHARMAVACCS LTD is a private company limited by shares and incorporated in England. Its registered office is:

117b Withington Road

Manchester

M16 8EE

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.